Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma
NCT03937843Phase 2Active, not recruiting
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Jul 2019
- Primary completion
- Dec 2026
- Modality
- Nanoparticles, DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
Phase 2, open-label trial of carboplatin, Cisplatin micelle injection (HA132) and etoposide in seminoma (2 cohorts), sponsored by Swiss Group for Clinical Cancer Research. Primary endpoint: Progression-Free Survival at 3 years. Started Jul 2019; status: active, not recruiting.
02
Drugs
carboplatinCisplatin micelle injection (HA132)etoposide
03
Conditions
seminoma
Beyond the preview
Go deeper on NCT03937843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03937843.